肿瘤细胞治疗研究
英文原题：Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.
胰腺导管腺癌（PDAC）是一种预后极差的致死性恶性肿瘤。
胰腺导管腺癌（PDAC）是一种致死性恶性肿瘤，预后极差。目前，化疗是大多数晚期PDAC患者的唯一选择。此外，传统免疫疗法和靶向疗法仅在罕见的PDAC患者亚组中改善生存结局。迄今为止，旨在克服免疫敌对的PDAC肿瘤微环境（TME）的联合免疫治疗策略在临床研究中疗效有限。然而，随着对TME、分子特征和免疫抵抗机制认识的不断深入，为PDAC患者开发新治疗策略的努力仍在持续。此外，不断增多的各种免疫治疗药物，包括新型免疫检查点抑制剂以及溶瘤、CAR-T 细胞和疫苗疗法，进一步强化了这些努力。本综述将聚焦免疫治疗在PDAC中的地位及未来可能的策略。
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a poor prognosis. Currently, chemotherapy is the only option for most patients with advanced-stage PDAC. Further, conventional immunotherapies and targeted therapies improve survival outcomes only in rare PDAC patient subgroups. To date, combinatory immunotherapeutic strategies to overcome the immune-hostile PDAC tumor microenvironment (TME) have resulted in limited efficacy in clinical studies. However, efforts are ongoing to develop new treatment strategies for patients with PDAC with the evolving knowledge of the TME, molecular characterization, and immune resistance mechanisms. Further, the growing arsenal of various immunotherapeutic agents, including novel classes of immune checkpoint inhibitors and oncolytic, chimeric antigen receptor T cell, and vaccine therapies, reinforces these efforts. This review will focus on the place of immunotherapy and future possible strategies in PDAC.
MEMBER ACCOUNT
登录成功会直接打开下一页。
